Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOGO Gogo	$15.87 +2.1%	$12.98	$6.17 ▼ $16.05	$2.06B	1.06	1.47 million shs	1.11 million shs
KSS Kohl's	$9.40 +1.4%	$8.49	$6.04 ▼ $23.02	$1.04B	1.66	9.06 million shs	4.05 million shs
KSS Kohl's	$9.40 +1.4%	$8.49	$6.04 ▼ $23.02	$1.04B	1.66	9.06 million shs	4.05 million shs
LLY Eli Lilly and Company	$788.91 +2.2%	$766.12	$677.09 ▼ $972.53	$731.42B	0.4	3.67 million shs	3.25 million shs
NTLA Intellia Therapeutics	$11.96 +4.2%	$9.31	$5.90 ▼ $28.18	$1.19B	2.21	3.04 million shs	3.67 million shs
VERV Verve Therapeutics	$11.02	$7.69	$2.86 ▼ $11.41	$982.36M	2.23	2.47 million shs	2.19 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOGO Gogo	+2.06%	+1.67%	+26.35%	+127.69%	+66.88%
KSS Kohl's	+1.44%	+0.09%	+5.13%	+45.26%	-58.06%
KSS Kohl's	+1.44%	+0.09%	+5.13%	+45.26%	-58.06%
LLY Eli Lilly and Company	+2.09%	+0.24%	-2.32%	-6.27%	-16.22%
NTLA Intellia Therapeutics	+4.18%	-1.40%	+33.48%	+65.42%	-56.27%
VERV Verve Therapeutics	0.00%	-0.63%	+75.76%	+140.09%	+40.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GOGO Gogo	1.7138 of 5 stars	1.3	1.0	0.0	0.0	2.9	4.2	1.9
KSS Kohl's	3.4521 of 5 stars	1.8	1.0	3.3	1.7	2.1	1.7	1.9
KSS Kohl's	3.4521 of 5 stars	1.8	1.0	3.3	1.7	2.1	1.7	1.9
LLY Eli Lilly and Company	4.9768 of 5 stars	4.4	4.0	3.3	4.0	2.9	1.7	1.9
NTLA Intellia Therapeutics	4.3808 of 5 stars	4.3	1.0	0.0	4.7	1.9	2.5	0.6
VERV Verve Therapeutics	3.0141 of 5 stars	4.2	3.0	0.0	0.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOGO Gogo	2.50	Moderate Buy	$12.63	-20.45% Downside
KSS Kohl's	1.53	Reduce	$9.75	3.75% Upside
KSS Kohl's	1.53	Reduce	$9.75	3.75% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,012.56	28.35% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	179.00% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	32.23% Upside

Current Analyst Ratings Breakdown

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$936.00 ➝ $942.00
7/10/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$1,133.00 ➝ $1,135.00
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/18/2025	GOGO Gogo	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$16.50
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOGO Gogo	$444.71M	4.72	$0.67 per share	23.76	$0.55 per share	28.85
KSS Kohl's	$16.22B	0.06	$8.32 per share	1.13	$34.15 per share	0.28
KSS Kohl's	$16.22B	0.06	$8.32 per share	1.13	$34.15 per share	0.28
LLY Eli Lilly and Company	$45.04B	16.60	$14.55 per share	54.22	$15.03 per share	52.49
NTLA Intellia Therapeutics	$57.88M	21.40	N/A	N/A	$8.56 per share	1.40
VERV Verve Therapeutics	$32.33M	30.38	N/A	N/A	$5.83 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOGO Gogo	$13.75M	-$0.04	N/A	31.74	N/A	-0.82%	95.01%	5.98%	8/6/2025 (Estimated)
KSS Kohl's	$109M	$1.09	8.62	7.70	N/A	0.75%	4.71%	1.27%	8/27/2025 (Estimated)
KSS Kohl's	$109M	$1.09	8.62	7.70	N/A	0.75%	4.71%	1.27%	8/27/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	64.19	25.35	1.12	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.56	N/A	N/A	N/A	$14.40 billion	N/A
8/6/2025	Q2 2025	GOGO Gogo	$0.12	N/A	N/A	N/A	$220.12 million	N/A
5/29/2025	Q1 2026	KSS Kohl's	-$0.22	-$0.13	+$0.09	-$0.13	$3.01 billion	$3.05 billion
5/29/2025	Q1 2026	KSS Kohl's	-$0.22	-$0.13	+$0.09	-$0.13	$3.01 billion	$3.05 billion
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/9/2025	Q1 2025	GOGO Gogo	$0.05	$0.18	+$0.13	$0.09	$214.93 million	$230.31 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOGO Gogo	N/A	N/A	N/A	N/A	N/A
KSS Kohl's	$0.50	5.32%	N/A	45.87%	N/A
KSS Kohl's	$0.50	5.32%	N/A	45.87%	N/A
LLY Eli Lilly and Company	$6.00	0.76%	N/A	48.82%	11 Years
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
5/14/2025	KSS Kohl's	quarterly	$0.1250	6.21%	6/11/2025	6/11/2025	6/25/2025
5/14/2025	KSS Kohl's	quarterly	$0.1250	6.21%	6/11/2025	6/11/2025	6/25/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOGO Gogo	10.03	1.84	1.36
KSS Kohl's	0.95	1.09	0.14
KSS Kohl's	0.95	1.09	0.14
LLY Eli Lilly and Company	2.18	1.37	1.06
NTLA Intellia Therapeutics	N/A	4.90	4.90
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOGO Gogo	69.60%
KSS Kohl's	98.04%
KSS Kohl's	98.04%
LLY Eli Lilly and Company	82.53%
NTLA Intellia Therapeutics	88.77%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
GOGO Gogo	25.78%
KSS Kohl's	1.00%
KSS Kohl's	1.00%
LLY Eli Lilly and Company	0.13%
NTLA Intellia Therapeutics	3.10%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOGO Gogo	380	132.26 million	98.17 million	Optionable
KSS Kohl's	87,000	112.04 million	110.92 million	Optionable
KSS Kohl's	87,000	112.04 million	110.92 million	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.40 million	Optionable

KSS, NTLA, GOGO, LLY, VERV, and KSS Headlines

Recent News About These Companies

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing

July 16 at 7:41 PM | thepharmaletter.comT

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)

...

July 15 at 4:27 PM | marketbeat.com

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

July 14 at 12:44 PM | msn.com

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

July 14 at 2:41 AM | msn.com

Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.

July 13, 2025 | hindustantimes.comH

Experimental treatment for high cholesterol edits DNA in the body to reduce LDL

July 11, 2025 | msn.com

Verve Therapeutics Inc News (VERV) - Investing.com

July 4, 2025 | investing.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Hold" by Analysts

July 3, 2025 | marketbeat.com

June’s Busy Buyout Binge Bolsters M&A Stats for H1

July 1, 2025 | biospace.comB

BMO Capital Markets Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 28, 2025 | marketbeat.com

BMO Capital Markets Reiterates Market Perform Rating for Verve Therapeutics (NASDAQ:VERV)

June 27, 2025 | marketbeat.com

VERV Verve Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Eli Lilly's Strategic Acquisition of Verve Therapeutics

June 24, 2025 | pharmiweb.comP

GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

June 24, 2025 | marketbeat.com

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

June 23, 2025 | insidermonkey.com

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

June 20, 2025 | fool.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

June 20, 2025 | globenewswire.com

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19, 2025 | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19, 2025 | insidenova.comI

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19, 2025 | msn.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
3 Stocks With Near-Unanimous Buys That Could Rally Higher
By Nathan Reiff | July 2, 2025
View 3 Stocks With Near-Unanimous Buys That Could Rally Higher
3 Notable Stocks Just Split: Which One Could Be the Big Winner?
By Leo Miller | June 26, 2025
View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?

KSS, NTLA, GOGO, LLY, VERV, and KSS Company Descriptions

Gogo NASDAQ:GOGO

$15.87 +0.32 (+2.06%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$15.65 -0.22 (-1.41%)

As of 05:41 AM Eastern

Gogo Inc., together with its subsidiaries, provides broadband connectivity services to the aviation industry in the United States and internationally. The company's product platform includes networks, antennas, and airborne equipment and software. It offers in-flight systems; in-flight services; aviation partner support; and engineering, design, and development services, as well as production operations functions. The company offers voice and data, in-flight entertainment, and other services. In addition, it engages in the development, deployment, and operation of networks, towers, and data center infrastructure to support in-flight connectivity services, as well as in the provision of telecommunications connections to the internet. The company sells its products primarily to aircraft operators and original equipment manufacturers of business aviation aircraft through a distribution network of independent dealers. Gogo Inc. was founded in 1991 and is headquartered in Broomfield, Colorado. As of May 2024, Gogo Inc. claims that "Gogo is the only company in North America with a complete, certified airborne 5G network, meaning that all components within the network (including onboard equipment) are 5G native."

Kohl's NYSE:KSS

$9.40 +0.13 (+1.38%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$9.40 0.00 (-0.03%)

As of 04:18 AM Eastern

Kohl's Corporation operates as an omnichannel retailer in the United States. It offers branded apparel, footwear, accessories, beauty, and home products through its stores and website. The company provides its products primarily under the brand names of Croft & Barrow, Jumping Beans, SO, Sonoma Goods for Life, and Tek Gear, as well as Food Network, LC Lauren Conrad, Nine West, and Simply Vera Vera Wang. Kohl's Corporation was founded in 1988 and is headquartered in Menomonee Falls, Wisconsin.

Kohl's NYSE:KSS

$9.40 +0.13 (+1.38%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$9.40 0.00 (-0.03%)

As of 04:18 AM Eastern

Eli Lilly and Company NYSE:LLY

$788.91 +17.16 (+2.22%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$789.06 +0.14 (+0.02%)

As of 05:47 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Intellia Therapeutics NASDAQ:NTLA

$11.96 +0.48 (+4.18%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$12.10 +0.14 (+1.13%)

As of 05:44 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics NASDAQ:VERV

$11.02 0.00 (0.00%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$11.02 0.00 (-0.05%)

As of 05:37 AM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Earnings

Compare Dividends

Latest KSS, NTLA, GOGO, LLY, VERV, and KSS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KSS, NTLA, GOGO, LLY, VERV, and KSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KSS, NTLA, GOGO, LLY, VERV, and KSS Company Descriptions

Gogo NASDAQ:GOGO

Kohl's NYSE:KSS

Kohl's NYSE:KSS

Eli Lilly and Company NYSE:LLY

Intellia Therapeutics NASDAQ:NTLA

Verve Therapeutics NASDAQ:VERV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools